Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity.
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
Arizona
/ epidemiology
Betacoronavirus
/ immunology
COVID-19
COVID-19 Testing
Clinical Laboratory Techniques
/ methods
Coronavirus Infections
/ blood
Coronavirus Nucleocapsid Proteins
Female
Humans
Immunity, Humoral
Male
Middle Aged
Nucleocapsid Proteins
/ immunology
Pandemics
Phosphoproteins
Pneumonia, Viral
/ blood
Prevalence
Protein Interaction Domains and Motifs
SARS-CoV-2
Seroepidemiologic Studies
Spike Glycoprotein, Coronavirus
/ chemistry
Young Adult
COVID-19
S2 domain
SARS-CoV-2
antibodies
neutralization
nucleocapsid protein
orthogonal serological tests
receptor binding domain
serological test
serology
spike protein
Journal
Immunity
ISSN: 1097-4180
Titre abrégé: Immunity
Pays: United States
ID NLM: 9432918
Informations de publication
Date de publication:
17 11 2020
17 11 2020
Historique:
received:
31
07
2020
revised:
01
10
2020
accepted:
05
10
2020
pubmed:
2
11
2020
medline:
1
12
2020
entrez:
1
11
2020
Statut:
ppublish
Résumé
We conducted a serological study to define correlates of immunity against SARS-CoV-2. Compared to those with mild coronavirus disease 2019 (COVID-19) cases, individuals with severe disease exhibited elevated virus-neutralizing titers and antibodies against the nucleocapsid (N) and the receptor binding domain (RBD) of the spike protein. Age and sex played lesser roles. All cases, including asymptomatic individuals, seroconverted by 2 weeks after PCR confirmation. Spike RBD and S2 and neutralizing antibodies remained detectable through 5-7 months after onset, whereas α-N titers diminished. Testing 5,882 members of the local community revealed only 1 sample with seroreactivity to both RBD and S2 that lacked neutralizing antibodies. This fidelity could not be achieved with either RBD or S2 alone. Thus, inclusion of multiple independent assays improved the accuracy of antibody tests in low-seroprevalence communities and revealed differences in antibody kinetics depending on the antigen. We conclude that neutralizing antibodies are stably produced for at least 5-7 months after SARS-CoV-2 infection.
Identifiants
pubmed: 33129373
pii: S1074-7613(20)30445-3
doi: 10.1016/j.immuni.2020.10.004
pmc: PMC7554472
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Coronavirus Nucleocapsid Proteins
0
Nucleocapsid Proteins
0
Phosphoproteins
0
Spike Glycoprotein, Coronavirus
0
nucleocapsid phosphoprotein, SARS-CoV-2
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
925-933.e4Subventions
Organisme : NIAID NIH HHS
ID : R01 AI129945
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG060900
Pays : United States
Organisme : NIA NIH HHS
ID : T32 AG058503
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI099108
Pays : United States
Organisme : NHLBI NIH HHS
ID : K08 HL141623
Pays : United States
Commentaires et corrections
Type : UpdateOf
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Interests Unrelated intellectual property of D.B. and Washington University has been licensed by Sana Biotechnology. J.N.Ž. is on the scientific advisory board of and receives research funding from Young Blood, Inc. R.S. is a founder and chief scientific officer of Geneticure. R.W. is currently an employee of Vir Biotechnology. A provisional patent application related to this work has been filed with the US Patent Office.
Références
Clin Transl Immunology. 2020 May 06;9(5):e01136
pubmed: 32382418
Immunol Rev. 2006 Jun;211:310-9
pubmed: 16824138
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
Immunity. 2020 Sep 15;53(3):524-532.e4
pubmed: 32783920
N Engl J Med. 2007 Sep 13;357(11):1162-3
pubmed: 17855683
J Exp Med. 2011 Dec 19;208(13):2599-606
pubmed: 22162833
Nat Immunol. 2012 May 06;13(6):604-11
pubmed: 22561605
Clin Infect Dis. 2021 Nov 2;73(9):e2946-e2951
pubmed: 32840608
Clin Infect Dis. 2020 Nov 19;71(16):2255-2258
pubmed: 32337590
Nature. 1997 Jul 10;388(6638):133-4
pubmed: 9217150
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Elife. 2020 Oct 28;9:
pubmed: 33112236
Biochem Biophys Res Commun. 2005 Jul 22;333(1):186-93
pubmed: 15939399
J Virol. 2004 Sep;78(17):9007-15
pubmed: 15308697
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32692348
Science. 2020 Oct 30;370(6516):564-570
pubmed: 32912998
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Sci Immunol. 2020 Jun 11;5(48):
pubmed: 32527802
J Immunol. 2016 Aug 15;197(4):1159-68
pubmed: 27357154
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Nature. 2021 Mar;591(7849):293-299
pubmed: 33494095
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
Annu Rev Virol. 2016 Sep 29;3(1):237-261
pubmed: 27578435
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Epidemiol Infect. 1990 Oct;105(2):435-46
pubmed: 2170159
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
Nat Immunol. 2014 Jul;15(7):631-7
pubmed: 24880458
Viruses. 2020 Mar 25;12(4):
pubmed: 32218151
Ann Epidemiol. 2020 Aug;48:23-29.e4
pubmed: 32648546
Immunity. 1998 Mar;8(3):363-72
pubmed: 9529153
Immunity. 2020 Nov 17;53(5):1078-1094.e7
pubmed: 33010224
J Clin Med. 2020 Jul 17;9(7):
pubmed: 32708872
Clin Vaccine Immunol. 2010 Dec;17(12):1875-80
pubmed: 20943876
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
Sci Rep. 2019 Oct 24;9(1):15257
pubmed: 31649328
N Engl J Med. 2007 Nov 8;357(19):1903-15
pubmed: 17989383
J Immunol. 2007 Nov 15;179(10):6808-19
pubmed: 17982071
EMBO J. 1997 Jun 2;16(11):2996-3006
pubmed: 9214617
Immunity. 2018 Jan 16;48(1):133-146.e6
pubmed: 29287996
Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2259-64
pubmed: 24469811
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033173
Int J Epidemiol. 2021 May 17;50(2):410-419
pubmed: 33615345
J Immunol. 2020 Nov 1;205(9):2342-2350
pubmed: 32887754
Emerg Infect Dis. 2020 Oct;26(10):2484-2487
pubmed: 32579877
J Infect. 2020 Jun;80(6):e14-e18
pubmed: 32171866
JAMA. 2020 Jul 14;324(2):195-197
pubmed: 32539107
J Med Virol. 1984;13(2):179-92
pubmed: 6319590
N Engl J Med. 2020 Sep 10;383(11):1085-1087
pubmed: 32706954
Emerg Microbes Infect. 2020 Dec;9(1):2368-2378
pubmed: 33151135
J Virol. 2003 Aug;77(16):8801-11
pubmed: 12885899
J Exp Med. 2000 Sep 18;192(6):813-21
pubmed: 10993912
J Immunol. 2011 Apr 1;186(7):3882-91
pubmed: 21339368
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Nat Commun. 2021 May 19;12(1):2938
pubmed: 34011939